These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 34991700)

  • 1. Myxopyronin B inhibits growth of a Fidaxomicin-resistant Clostridioides difficile isolate and interferes with toxin synthesis.
    Brauer M; Herrmann J; Zühlke D; Müller R; Riedel K; Sievers S
    Gut Pathog; 2022 Jan; 14(1):4. PubMed ID: 34991700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a clinical Clostridioides difficile isolate with markedly reduced fidaxomicin susceptibility and a V1143D mutation in rpoB.
    Schwanbeck J; Riedel T; Laukien F; Schober I; Oehmig I; Zimmermann O; Overmann J; Groß U; Zautner AE; Bohne W
    J Antimicrob Chemother; 2019 Jan; 74(1):6-10. PubMed ID: 30247587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fidaxomicin inhibits Clostridium difficile toxin A-mediated enteritis in the mouse ileum.
    Koon HW; Ho S; Hing TC; Cheng M; Chen X; Ichikawa Y; Kelly CP; Pothoulakis C
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4642-50. PubMed ID: 24890583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fidaxomicin inhibits spore production in Clostridium difficile.
    Babakhani F; Bouillaut L; Gomez A; Sears P; Nguyen L; Sonenshein AL
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S162-9. PubMed ID: 22752866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis.
    Artsimovitch I; Seddon J; Sears P
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S127-31. PubMed ID: 22752861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. U.S.-Based National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile-Associated Diarrheal Isolates from 2013 to 2016.
    Thorpe CM; McDermott LA; Tran MK; Chang J; Jenkins SG; Goldstein EJC; Patel R; Forbes BA; Johnson S; Gerding DN; Snydman DR
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31085514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fidaxomicin reduces early toxin A and B production and sporulation in Clostridium difficilein vitro.
    Aldape MJ; Packham AE; Heeney DD; Rice SN; Bryant AE; Stevens DL
    J Med Microbiol; 2017 Oct; 66(10):1393-1399. PubMed ID: 28893366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effect of fidaxomicin on biofilm formation in Clostridioides difficile.
    Hamada M; Yamaguchi T; Ishii Y; Chono K; Tateda K
    J Infect Chemother; 2020 Jul; 26(7):685-692. PubMed ID: 32224190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antimicrobial profile and clinical evidence of fidaxomicin (Dafclir
    Takeda S; Miki T
    Nihon Yakurigaku Zasshi; 2019; 154(4):217-229. PubMed ID: 31597902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile.
    Babakhani F; Seddon J; Sears P
    Antimicrob Agents Chemother; 2014 May; 58(5):2934-7. PubMed ID: 24550338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of selenoprotein synthesis is not the mechanism by which auranofin inhibits growth of Clostridioides difficile.
    Johnstone MA; Holman MA; Self WT
    Sci Rep; 2023 Sep; 13(1):14733. PubMed ID: 37679389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic Resistances and Molecular Characteristics of
    Meng X; Huang X; Peng Z; Wang Y; Liu S; Zeng C; Duan J; Wen X; Fu C; Wu A; Li C
    Front Med (Lausanne); 2021; 8():745383. PubMed ID: 34938744
    [No Abstract]   [Full Text] [Related]  

  • 13. Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan.
    Liao CH; Ko WC; Lu JJ; Hsueh PR
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3943-9. PubMed ID: 22508299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of the novel antibacterial agent ibezapolstat (ACX-362E) against Clostridioides difficile.
    Murray B; Wolfe C; Marra A; Pillar C; Shinabarger D
    J Antimicrob Chemother; 2020 Aug; 75(8):2149-2155. PubMed ID: 32285102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.
    Goldstein EJ; Citron DM; Sears P; Babakhani F; Sambol SP; Gerding DN
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5194-9. PubMed ID: 21844318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic Resistance and Toxin Production of
    Peng Z; Addisu A; Alrabaa S; Sun X
    Front Microbiol; 2017; 8():2584. PubMed ID: 29312258
    [No Abstract]   [Full Text] [Related]  

  • 17. Fidaxomicin inhibits toxin production in Clostridium difficile.
    Babakhani F; Bouillaut L; Sears P; Sims C; Gomez A; Sonenshein AL
    J Antimicrob Chemother; 2013 Mar; 68(3):515-22. PubMed ID: 23208832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fidaxomicin for the treatment of
    Skinner AM; Scardina T; Kociolek LK
    Future Microbiol; 2020 Jul; 15(11):967-979. PubMed ID: 32715754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in the susceptibility of commonly encountered clinically significant anaerobes and susceptibilities of blood isolates of anaerobes to 16 antimicrobial agents, including fidaxomicin and rifaximin, 2008-2012, northern Taiwan.
    Wang FD; Liao CH; Lin YT; Sheng WH; Hsueh PR
    Eur J Clin Microbiol Infect Dis; 2014 Nov; 33(11):2041-52. PubMed ID: 24930042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the antimicrobial activity of ridinilazole and six comparators against Chinese, Japanese and South Korean strains of Clostridioides difficile.
    Collins DA; Wu Y; Tateda K; Kim HJ; Vickers RJ; Riley TV
    J Antimicrob Chemother; 2021 Mar; 76(4):967-972. PubMed ID: 33351917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.